Get the Stockscreener App
27.12
3.07%
-0.86
After Hours:
27.12
Atricure Inc stock is traded at $27.12, with a volume of 828.80K.
It is down -3.07% in the last 24 hours and down -3.56% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$27.98
Open:
$27.61
24h Volume:
828.80K
Relative Volume:
1.10
Market Cap:
$1.37B
Revenue:
$534.53M
Net Income/Loss:
$-11.45M
P/E Ratio:
-112.48
EPS:
-0.2411
Net Cash Flow:
$48.28M
1W Performance:
-1.42%
1M Performance:
-3.56%
6M Performance:
-33.55%
1Y Performance:
-16.81%
1-Day Range:
$26.81
$28.45
1-Week Range:
$26.81
$29.14
52-Week Range:
$25.36
$43.18
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
27.12 | 1.42B | 534.53M | -11.45M | 48.28M | -0.2411 |
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-11-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
Trading Systems Reacting to (ATRC) Volatility - Stock Traders Daily
Do options traders know something about AtriCure stock we don't? - MSN
AtriCure (ATRC) Q1 2026 Earnings Transcript - AOL.com
Do Options Traders Know Something About AtriCure Stock We Don't? - Yahoo Finance
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention - Yahoo Finance
AtriCure faces market doubts despite revenue growth; share prices fall. Insider optimism hints at potential turnaround, but long-term earnings are the focus. - Moomoo
AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule - Insider Monkey
AtriCure, Inc. Hits 52-Week Low at USD 25.37 Amid Market Struggles - Markets Mojo
AtriCure stock hits 52-week low at 25.51 USD By Investing.com - Investing.com Australia
AtriCure stock hits 52-week low at 25.51 USD - Investing.com
Top 10 Small Cap Stocks With Huge Growth Potential - Insider Monkey
AtriCure Inc. (ATRC) Slips 1.5% as Stock Hovers Near Key Support at $26.29Chart Pattern Alerts - The Legal Advocate
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference - Yahoo Finance
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) - GuruFocus
(ATRC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AtriCure director Karen Prange sells $85,950 in company stock By Investing.com - Investing.com Canada
AtriCure director Karen Prange sells $85,950 in company stock - Investing.com
AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373 - Stock Titan
Director Karen Prange granted 6,144 AtriCure (ATRC) shares - Stock Titan
AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares - Stock Titan
AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award - Stock Titan
Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares - Stock Titan
Director Kristine Johnson receives 6,144-share grant at AtriCure (ATRC) - Stock Titan
AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant - Stock Titan
AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant - Stock Titan
Director at AtriCure (ATRC) receives 6,144-share restricted stock grant - Stock Titan
[144] AtriCure, Inc. SEC Filing - Stock Titan
AtriCure Shareholders Approve Expanded Equity and Governance Plans - TipRanks
AtriCure (ATRC) stockholders back equity plan share increases and director slate - Stock Titan
AtriCure conference: New devices, EnCompass drive 2026 growth outlook - MSN
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13 - Stock Titan
AtriCure Inc Annual Shareholders Meeting Transcript - GuruFocus
How AtriCure scaled legal operations with Thomson Reuters - Thomson Reuters Legal Solutions
Loss-Making AtriCure, Inc. (NASDAQ:ATRC) Set To Breakeven - Moomoo
ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals - Stock Titan
Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake - Stock Titan
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tel - GuruFocus
AtriCure stock (US04963C1099): Q1 revenue jumps 14% to $141M amid return to profit - AD HOC NEWS
AtriCure, Inc.Common Stock (NQ: ATRC - FinancialContent
AtriCure (ATRC) Is Down 5.1% After Q1 Return To Profitability And Higher Revenue Guidance – What's Changed - simplywall.st
TradingKey - TradingKey
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook - sharewise.com
ATRC: Innovation, clinical trials, and new launches drive growth and reinforce market leadership - TradingView
Transcript : AtriCure, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10 - marketscreener.com
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):